New drug trial aims to break vicious cycle in heart failure
NCT ID NCT06027307
Summary
This study is testing whether a drug called enavogliflozin can help people who have heart failure along with a leaky tricuspid heart valve. About 541 participants will take the drug or a placebo for 18 months to see if it reduces serious heart-related events, hospital visits, or worsening of the valve leak. The goal is to see if this medication can better control the disease and improve outcomes for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Inha University Hospital
Incheon, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Yonsei University Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.